Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

Uçaktürk E, Nemutlu E

Journal of pharmaceutical and biomedical analysis20 Oct 2025

PMID41138283DOI10.1016/j.jpba.2025.117207PepBankPUB-41138283

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of CJC-1295 (with DAC) aloneOther designOther
A nano-LC-Q/Orbitrap MS method detected CJC‑1295 in urine with a limit of detection of 0.5 ng/mL or lower.
In plain wordsA lab method detected CJC‑1295 in urine at 0.5 ng/mL or lower.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableLimit of detection in urine
Study
n: not reported in source
Urine, nano-LC-Q/Orbitrap MS method
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
≤ 0.5 ng/mL
urine
Source sentences
Summary
Achieved LODs (≤ 0.5 ng/mL) and LOIs (0.5-0.75 ng/mL) demonstrated sufficient sensitivity for effective detection and confirmation analysis of the target peptides in urine.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary metabolite of sermorelin in urine,…
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-4113828301
02LabNot a test of CJC-1295 (with DAC) aloneOther designOther
A nano-LC-Q/Orbitrap MS method confirmed CJC‑1295 in urine with a limit of identification of 0.5 to 0.75 ng/mL.
In plain wordsA lab method confirmed CJC‑1295 in urine at 0.5 to 0.75 ng/mL.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableLimit of identification in urine
Study
n: not reported in source
Urine, nano-LC-Q/Orbitrap MS method
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOI
0.5 to 0.75 ng/mL
urine
Source sentences
Summary
Achieved LODs (≤ 0.5 ng/mL) and LOIs (0.5-0.75 ng/mL) demonstrated sufficient sensitivity for effective detection and confirmation analysis of the target peptides in urine.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary metabolite of sermorelin in urine,…
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-4113828302
03LabNot a test of CJC-1295 (with DAC) aloneOther designOther
Validation according to WADA guidelines confirmed that the method is suitable and robust for anti-doping testing of the target peptides, including CJC‑1295.
In plain wordsA lab method for finding CJC‑1295 in urine passed validation for anti-doping testing.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableMethod validation for anti-doping testing
Study
n: not reported in source
Urine, nano-LC-Q/Orbitrap MS method
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
The validation results confirmed the method's suitability and robustness for anti-doping testing.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary metabolite of sermorelin in urine,…
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-4113828303
04LabNot a test of Tesamorelin aloneOther designOther
A nano-LC-Q/Orbitrap MS method detected tesamorelin in urine with a limit of detection of 0.5 ng/mL or lower.
In plain wordsA lab method detected tesamorelin in urine at 0.5 ng/mL or lower.
Peptide
Tesamorelin
Outcome
Not applicableLimit of detection in urine
Study
n: not reported in source
Urine, nano-LC-Q/Orbitrap MS method
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
≤ 0.5 ng/mL
urine
Source sentences
Summary
Achieved LODs (≤ 0.5 ng/mL) and LOIs (0.5-0.75 ng/mL) demonstrated sufficient sensitivity for effective detection and confirmation analysis of the target peptides in urine.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary metabolite of sermorelin in urine,…
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-4113828304
05LabNot a test of Tesamorelin aloneOther designOther
A nano-LC-Q/Orbitrap MS method confirmed tesamorelin in urine with a limit of identification of 0.5 to 0.75 ng/mL.
In plain wordsA lab method confirmed tesamorelin in urine at 0.5 to 0.75 ng/mL.
Peptide
Tesamorelin
Outcome
Not applicableLimit of identification in urine
Study
n: not reported in source
Urine, nano-LC-Q/Orbitrap MS method
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOI
0.5 to 0.75 ng/mL
urine
Source sentences
Summary
Achieved LODs (≤ 0.5 ng/mL) and LOIs (0.5-0.75 ng/mL) demonstrated sufficient sensitivity for effective detection and confirmation analysis of the target peptides in urine.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary metabolite of sermorelin in urine,…
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-4113828305
06LabNot a test of Tesamorelin aloneOther designOther
Validation according to WADA guidelines confirmed that the method is suitable and robust for anti-doping testing of the target peptides, including tesamorelin.
In plain wordsA lab method for finding tesamorelin in urine passed validation for anti-doping testing.
Peptide
Tesamorelin
Outcome
Not applicableMethod validation for anti-doping testing
Study
n: not reported in source
Urine, nano-LC-Q/Orbitrap MS method
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
The validation results confirmed the method's suitability and robustness for anti-doping testing.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary metabolite of sermorelin in urine,…
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-4113828306
07LabNot a test of Sermorelin aloneOther designOther
A nano-LC-Q/Orbitrap MS method for GHRH analogs including sermorelin in urine reached limits of detection of 0.5 ng/mL or lower.
In plain wordsA lab method detected sermorelin and related peptides in urine at very low levels, 0.5 ng/mL or lower.
Peptide
Sermorelin
Outcome
Not applicableLimit of detection in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
≤ 0.5 ng/mL
GHRH analogs in urine
Source sentences
Summary
Achieved LODs (≤ 0.5 ng/mL) and LOIs (0.5-0.75 ng/mL) demonstrated sufficient sensitivity for effective detection and confirmation analysis of the target peptides in urine.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary metabolite of sermorelin in urine,…
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-4113828307
08LabNot a test of Sermorelin aloneOther designOther
The same method reached limits of identification of 0.5-0.75 ng/mL for GHRH analogs including sermorelin in urine.
In plain wordsThe lab method could confirm the identity of sermorelin and related peptides in urine at 0.5 to 0.75 ng/mL.
Peptide
Sermorelin
Outcome
Not applicableLimit of identification in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOI
0.5 to 0.75 ng/mL
GHRH analogs in urine
Source sentences
Summary
Achieved LODs (≤ 0.5 ng/mL) and LOIs (0.5-0.75 ng/mL) demonstrated sufficient sensitivity for effective detection and confirmation analysis of the target peptides in urine.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary metabolite of sermorelin in urine,…
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-4113828308
09LabNot a test of Sermorelin aloneOther designOther
The nano-LC-Q/Orbitrap MS method for GHRH analogs in urine was validated according to WADA guidelines and found suitable and robust for anti-doping testing.
In plain wordsA lab method for detecting sermorelin and related peptides in urine passed anti-doping validation checks.
Peptide
Sermorelin
Outcome
Not applicableMethod validation against WADA guidelines
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
The proposed method was fully validated according to WADA guidelines, assessing key parameters such as selectivity, reliability, limits of detection (LOD), carryover, limits of identification (LOI), robustness, autosampler stability, and matrix effects. The validation results confirmed the method's…
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary metabolite of sermorelin in urine,…
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-4113828309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 39Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Versions 2 to 3
9 Oct 2026, 03:13 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:13 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.